JP6985368B2 - バルプロ酸を含む遅延放出性薬学的製剤、及びその使用 - Google Patents

バルプロ酸を含む遅延放出性薬学的製剤、及びその使用 Download PDF

Info

Publication number
JP6985368B2
JP6985368B2 JP2019503794A JP2019503794A JP6985368B2 JP 6985368 B2 JP6985368 B2 JP 6985368B2 JP 2019503794 A JP2019503794 A JP 2019503794A JP 2019503794 A JP2019503794 A JP 2019503794A JP 6985368 B2 JP6985368 B2 JP 6985368B2
Authority
JP
Japan
Prior art keywords
vpa
pharmaceutically acceptable
acid
pai
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019503794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510834A5 (enExample
JP2019510834A (ja
Inventor
ニルス・オーヴェ・グスタフソン
ハンス・ロイエル・マルクス・モルテンソン
ニクラス・ベリ
ヨナス・ファイェルソン・サリョ
スヴェルケル・イェルン
Original Assignee
セレノ・サイエンティフィック・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレノ・サイエンティフィック・アーベー filed Critical セレノ・サイエンティフィック・アーベー
Publication of JP2019510834A publication Critical patent/JP2019510834A/ja
Publication of JP2019510834A5 publication Critical patent/JP2019510834A5/ja
Application granted granted Critical
Publication of JP6985368B2 publication Critical patent/JP6985368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019503794A 2016-04-08 2017-04-10 バルプロ酸を含む遅延放出性薬学的製剤、及びその使用 Active JP6985368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1606197.0 2016-04-08
GB201606197 2016-04-08
PCT/GB2017/051002 WO2017175013A1 (en) 2016-04-08 2017-04-10 Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Publications (3)

Publication Number Publication Date
JP2019510834A JP2019510834A (ja) 2019-04-18
JP2019510834A5 JP2019510834A5 (enExample) 2020-05-21
JP6985368B2 true JP6985368B2 (ja) 2021-12-22

Family

ID=58709491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503794A Active JP6985368B2 (ja) 2016-04-08 2017-04-10 バルプロ酸を含む遅延放出性薬学的製剤、及びその使用

Country Status (14)

Country Link
US (2) US11395808B2 (enExample)
EP (1) EP3439649B1 (enExample)
JP (1) JP6985368B2 (enExample)
KR (1) KR102438395B1 (enExample)
CN (2) CN109414423A (enExample)
AU (1) AU2017246697B2 (enExample)
ES (1) ES2969021T3 (enExample)
HU (1) HUE064701T2 (enExample)
IL (1) IL262163B2 (enExample)
MX (1) MX395521B (enExample)
PL (1) PL3439649T3 (enExample)
RU (1) RU2760304C2 (enExample)
WO (1) WO2017175013A1 (enExample)
ZA (1) ZA201806766B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
US11395808B2 (en) 2016-04-08 2022-07-26 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
CN113995742B (zh) * 2021-10-22 2023-12-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途
GB2613900B (en) * 2021-12-20 2024-01-17 Cereno Scient Ab Novel compounds and methods of use thereof
WO2026068561A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Valproic acid for use in treating pulmonary arterial hypertension

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
HK1042427A1 (zh) * 1999-09-30 2002-08-16 Penwest Pharmaceuticals Co. 用於高溶度药物的持续释放基质方法
AT408718B (de) * 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
JP2006507297A (ja) 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) 2003-04-21 2004-11-11 Samn Raffaniello Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006117165A2 (en) 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
CA2621560A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
EP1937650B1 (en) 2005-09-08 2011-06-15 S*BIO Pte Ltd Heterocyclic compounds
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
ES2317450T3 (es) * 2006-01-11 2009-04-16 Teva Pharmaceutical Industries Ltd. Formulacion de liberacion controlada de acido valproico y sus derivados.
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
EP2004234A2 (en) 2006-04-06 2008-12-24 Novartis AG Combination of organic compounds
NZ575171A (en) 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
CN101947209B (zh) * 2010-07-21 2012-07-25 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
PL2683371T3 (pl) * 2011-03-09 2021-04-19 Cereno Scientific Ab Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowej
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
CN104248627A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 丙戊酸半钠泡腾干混悬剂及其制备方法
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
WO2017175010A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
US11395808B2 (en) 2016-04-08 2022-07-26 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Also Published As

Publication number Publication date
CA3018043A1 (en) 2017-10-12
AU2017246697B2 (en) 2022-06-02
JP2019510834A (ja) 2019-04-18
MX395521B (es) 2025-03-25
ES2969021T3 (es) 2024-05-16
US12023311B2 (en) 2024-07-02
AU2017246697A1 (en) 2018-10-04
WO2017175013A1 (en) 2017-10-12
CN114209667A (zh) 2022-03-22
NZ746269A (en) 2024-10-25
US20230120670A1 (en) 2023-04-20
EP3439649C0 (en) 2023-11-15
EP3439649B1 (en) 2023-11-15
RU2018137399A3 (enExample) 2020-06-18
MX2018012224A (es) 2019-05-16
IL262163B1 (en) 2023-03-01
EP3439649A1 (en) 2019-02-13
ZA201806766B (en) 2024-03-27
HUE064701T2 (hu) 2024-04-28
US20190111011A1 (en) 2019-04-18
PL3439649T3 (pl) 2024-03-18
US11395808B2 (en) 2022-07-26
RU2760304C2 (ru) 2021-11-23
IL262163B2 (en) 2023-07-01
CN109414423A (zh) 2019-03-01
BR112018070626A2 (pt) 2019-02-05
IL262163A (en) 2018-11-29
KR20180127480A (ko) 2018-11-28
RU2018137399A (ru) 2020-05-12
KR102438395B1 (ko) 2022-08-30

Similar Documents

Publication Publication Date Title
JP6787901B2 (ja) 過度のフィブリン沈着及び／または血栓形成に関連する病理学的状態の治療または予防のための化合物及び組成物
US12023311B2 (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
RU2603471C2 (ru) Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения
US20230364089A1 (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
KR20180054655A (ko) 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
BR112018070626B1 (pt) Formulação farmacêutica e uso da mesma
WO2019226150A1 (en) Composition and methods for treating sleep disorders
BR112014007876B1 (pt) Forma de dosagem, composição, processo para preparação de uma composição, uso de uma composição
HK40004470A (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
HK40004470B (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
HK40089307A (en) Medical application of valproic acid
MX2012013970A (es) Composiciones farmaceuticas de ibuprofeno y un antagonista del receptor de h2.
CN108289891A (zh) 缓解尿频的组合物，其制造方法和应用
HK1245627A1 (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
CN105106962A (zh) 一种复方降压制剂及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211125

R150 Certificate of patent or registration of utility model

Ref document number: 6985368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250